Johnson & Johnson vs. Nektar Therapeutics
Johnson & Johnson (JNJ) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| JNJ | NKTR | |
|---|---|---|
| Market Cap | $628.65 billion | $2.57 billion |
| Revenue (TTM) | $97.93 billion | $55.63 million |
| Net Income (TTM) | $21.04 billion | $-158,098,000 |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| JNJ | NKTR | |
|---|---|---|
| P/E Ratio | 30.20 | — |
| Price / Book | 7.40 | 4.46 |
| Price / Sales | 6.42 | 46.17 |
JNJ and NKTR split the valuation factors evenly.
Profitability
| JNJ | NKTR | |
|---|---|---|
| Net Margin | 21.48% | -284.18% |
| Return on Equity | 24.76% | -27.44% |
JNJ leads on 2 of 2 profitability factors.
Dividend
| JNJ | NKTR | |
|---|---|---|
| Dividend Yield | 2.06% | — |
| Payout Ratio | 62.18 | — |
JNJ and NKTR split the dividend factors evenly.
Risk & Sentiment
| JNJ | NKTR | |
|---|---|---|
| Short Interest | 0.67% | 31.57% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, NKTR overview, NKTR financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.